K57 Pill Identification
The tablet imprinted with K57 is a prescription single-entity opioid analgesic. It is a generic form of immediate-release Oxycodone Hydrochloride 20 mg.
- Attribute Specification
- Active Ingredient – Oxycodone Hydrochloride (20 mg)
- Appearance – Round, light-gray (may appear gray-blue under certain light), uncoated tablet
- Imprint – “K 57” on one side, single score line on the reverse
- Manufacturer – KVK-Tech, Inc.
- Drug Class – Opioid / Narcotic Analgesic
- DEA Schedule – Schedule II Controlled Substance
Mechanism of Action
Oxycodone is a semi-synthetic opioid agonist that provides analgesic relief through specific interaction with central nervous system (CNS) pathways:
- Opioid Receptor Binding: Oxycodone acts primarily as a full agonist at the opioid receptors distributed throughout the brain and spinal cord.
- Inhibition of Pain Pathways: Binding closes presynaptic voltage-gated calcium channels and opens postsynaptic potassium channels. This hyperpolarizes neuronal membranes, inhibiting the release of substance P and glutamate, thereby blocking pain signal transmission along ascending nociceptive pathways.
- Altered Perception: Beyond physically dampening pain signals, its central actions alter the psychological and emotional perception of pain, frequently producing feelings of sedation and mild euphoria.
Therapeutic Indications & Dosage
Standard Uses
Prescribed strictly for the management of acute, moderate-to-severe pain severe enough to require an opioid analgesic and for which alternative treatments (non-opioids) are inadequate or not tolerated.
Standard Dosage Guidance
- Adult Dosage: Standard immediate-release dosing typically starts at 5 mg to 15 mg every 4 to 6 hours as needed for pain. A 20 mg single-tablet strength like K57 is generally reserved for opioid-tolerant patients or those with higher analgesic requirements.
- Administration: May be taken with or without food. Taking it with food or milk may help minimize mild stomach upset.
- Duration: Should be prescribed for the shortest necessary period to minimize risks of tolerance, dependence, and physical habituation.
Side Effects
Common Side Effects
- Drowsiness, sedation, or lethargy
- Dizziness or lightheadedness
- Nausea and vomiting
- Severe constipation (requires adequate hydration, dietary fiber, or stool softeners)
- Pruritus (itching) and dry mouth
Severe Side Effects (Seek Immediate Medical Emergency Care)
- Respiratory Depression: Abnormally slow, shallow, or irregular breathing.
- Central CNS Depression: Extreme sleepiness, inability to stay awake, or unresponsiveness.
- Severe Hypotension: Sudden drop in blood pressure, leading to syncope (fainting) or severe lightheadedness upon standing.
- Adrenal Insufficiency: Nausea, vomiting, loss of appetite, severe fatigue, or dizziness (typically with prolonged use).
FDA Boxed Warnings & Major Risks
- Addiction, Abuse, and Misuse: As a Schedule II narcotic, oxycodone carries a substantial risk of physical dependence, psychological addiction, abuse, and misuse.
- Life-Threatening Respiratory Depression: Serious, life-threatening, or fatal respiratory depression can occur at any point during therapy, especially during treatment initiation or following a dose escalation.
- Accidental Ingestion: Ingestion of even a single tablet by anyone other than the prescribed patient—especially children – can cause a fatal overdose.
- Interaction with CNS Depressants & Benzodiazepines: Simultaneous use of opioids with benzodiazepines, sedatives, or alcohol can cause severe respiratory depression, profound sedation, coma, and death.
- CYP3A4 Interactions: Concomitant use with drugs that inhibit CYP3A4 enzymes (or stopping CYP3A4 inducers) can increase plasma concentrations of oxycodone, elevating overdose risk.
- Neonatal Opioid Withdrawal Syndrome (NOWS): Extended use during pregnancy can lead to drug withdrawal in the newborn, which can be fatal if unrecognized and untreated.
Critical Precautions & Interventions
- Alcohol Avoidance: Do not drink alcohol or consume medications containing alcohol while taking K57. Alcohol markedly accentuates the CNS depressant effect, raising the risk of fatal overdose.
- Medical Conditions: Inform your healthcare provider before use if you have a history of severe asthma, COPD, paralytic ileus (bowel obstruction), head injuries, liver or kidney impairment, or prior substance use disorder.
- Overdose Response (Naloxone): Keep Naloxone (Narcan) accessible. Signs of an overdose include pinpoint pupils, loss of consciousness, cold/clammy skin, and shallow or stopped breathing. Call 911 immediately if an overdose is suspected.
- Illicit Counterfeit Risk: Unregulated grey or blue tablets bearing “K 57” markings sold outside licensed pharmacies carry an extreme risk of containing lethal amounts of illicit fentanyl. Only consume pills received directly from a licensed, verified pharmacy.